1.	MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 to 75 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: UMAN-10-01, NCT01628471
2.	Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 18 Sponsor: NCI, Other Protocol IDs: CDR0000554969, P30CA012197, CCCWFU-85106, CCCWFU-IRB00000371, NCT00499408
3.	Genistein in Treating Patients With Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: NCI 09U2, NCI-2010-00941, STU00019487, P50CA090386, NCT01126879
4.	Study of Cholecalciferol and Daily Genistein (G-2535) Versus Placebo in Men With Early Stage Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UWI09-14-01, NCT01325311
5.	Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment Phase: Phase II Type: Supportive care Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: IRB00050273, NCT01489813
6.	Prostate Cancer Prevention Trial With Quercetin and Genistein Phase: No phase specified Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: ZEM 21 AII, NCT01538316